Last reviewed · How we verify
TIVOZANIB
At a glance
| Generic name | TIVOZANIB |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Decreased appetite
- Nausea
- Dysphonia
- Hypothyroidism
- Cough
- Stomatitis
- Sodium decreased
- Lipase increased
- Phosphate decreased
Serious adverse events
- Bleeding
- Venous thromboembolism
- Arterial thromboembolism
- Acute kidney injury
- Hepatobiliary disorders
- Pneumonia
- Respiratory failure
- Myocardial infarction
- Cerebrovascular accident
- Subdural hematoma
Key clinical trials
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (PHASE1, PHASE2)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (PHASE2)
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (PHASE3)
- Tivozanib + Enzalutamide in Adv Prostate Cancer (PHASE2)
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (PHASE1, PHASE2)
- Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIVOZANIB CI brief — competitive landscape report
- TIVOZANIB updates RSS · CI watch RSS